Patents by Inventor Abbot F. Clark

Abbot F. Clark has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Transferrin/transferrin receptor-mediated siRNA delivery
    Patent number: 10138483
    Abstract: The invention provides interfering RNA molecule-ligand conjugates useful as a delivery system for delivering interfering RNA molecules to a cell in vitro or in vivo. The conjugates comprise a ligand that can bind to a transferrin receptor (TfR). Therapeutic uses for the conjugates are also provided.
    Type: Grant
    Filed: February 6, 2017
    Date of Patent: November 27, 2018
    Assignee: Arrowhead Pharmaceuticals, Inc.
    Inventors: Jon E. Chatterton, Abbot F. Clark
  • RNAi-mediated inhibition of connexin 43 for treatment of IOP-related conditions
    Patent number: 9752147
    Abstract: RNA interference is provided for inhibition of connexin 43 (Cx43) in intraocular pressure-related conditions, including ocular hypertension and glaucoma such as normal tension glaucoma and open angle glaucoma.
    Type: Grant
    Filed: September 27, 2016
    Date of Patent: September 5, 2017
    Assignee: Arrowhead Pharmaceuticals, Inc.
    Inventors: Jon E. Chatterton, Abbot F. Clark, Martin B. Wax
  • TRANSFERRIN/TRANSFERRIN RECEPTOR-MEDIATED siRNA DELIVERY
    Publication number: 20170145415
    Abstract: The invention provides interfering RNA molecule-ligand conjugates useful as a delivery system for delivering interfering RNA molecules to a cell in vitro or in vivo. The conjugates comprise a ligand that can bind to a transferrin receptor (TfR). Therapeutic uses for the conjugates are also provided.
    Type: Application
    Filed: February 6, 2017
    Publication date: May 25, 2017
    Inventors: Jon E. Chatterton, Abbot F. Clark
  • RNAi-Mediated Inhibition of Frizzled Related Protein-1 for Treatment of Glaucoma
    Publication number: 20170073681
    Abstract: RNA interference is provided for inhibition of Frizzled Related Protein-1 mRNA expression, in particular, for treating patients having glaucoma or at risk of developing glaucoma.
    Type: Application
    Filed: November 30, 2016
    Publication date: March 16, 2017
    Inventors: Abbot F. Clark, Wan-Heng Wang, Loretta Graves McNatt, Jon E. Chatterton
  • Transferrin/transferrin receptor-mediated siRNA delivery
    Patent number: 9562230
    Abstract: The invention provides interfering RNA molecule-ligand conjugates useful as a delivery system for delivering interfering RNA molecules to a cell in vitro or in vivo. The conjugates comprise a ligand that can bind to a transferrin receptor (TfR). Therapeutic uses for the conjugates are also provided.
    Type: Grant
    Filed: July 16, 2015
    Date of Patent: February 7, 2017
    Assignee: Arrowhead Pharmaceuticals, Inc.
    Inventors: Jon E. Chatterton, Abbot F. Clark
  • RNAI-mediated inhibition of frizzled related protein-1 for treatment of glaucoma
    Patent number: 9550994
    Abstract: RNA interference is provided for inhibition of Frizzled Related Protein-1 mRNA expression, in particular, for treating patients having glaucoma or at risk of developing glaucoma.
    Type: Grant
    Filed: April 21, 2015
    Date of Patent: January 24, 2017
    Assignee: Arrowhead Pharmaceuticals, Inc.
    Inventors: Abbot F. Clark, Wan-Heng Wang, Loretta Graves McNatt, Jon E Chatterton
  • RNAi-MEDIATED INHIBITION OF CONNEXIN 43 FOR TREATMENT OF IOP-RELATED CONDITIONS
    Publication number: 20170009235
    Abstract: RNA interference is provided for inhibition of connexin 43 (Cx43) in intraocular pressure-related conditions, including ocular hypertension and glaucoma such as normal tension glaucoma and open angle glaucoma.
    Type: Application
    Filed: September 27, 2016
    Publication date: January 12, 2017
    Inventors: Jon E. Chatterton, Abbot F. Clark, Martin B. Wax
  • RNAi-Related Inhibition of TNF-alpha Signaling Pathway for Treatment of Ocular Angiogenesis
    Publication number: 20160326533
    Abstract: RNA interference is provided for inhibition of tumor necrosis factor ? (TNF?) by silencing TNF? cell surface receptor TNF receptor-1 (TNFR1) mRNA expression, or by silencing TNF? converting enzyme (TACE/ADAM17) mRNA expression. Silencing such TNF? targets, in particular, is useful for treating patients having a TNF?-related condition or at risk of developing a TNF?-related condition, such as ocular angiogenesis, retinal ischemia, and diabetic retinopathy.
    Type: Application
    Filed: July 25, 2016
    Publication date: November 10, 2016
    Inventors: Jon E. Chatterton, Abbot F. Clark, David P. Bingaman, Martin B. Wax, Adrian M. Timmers
  • RNAi-mediated inhibition of connexin 43 for treatment of IOP-related conditions
    Patent number: 9476047
    Abstract: RNA interference is provided for inhibition of connexin 43 (Cx43) in intraocular pressure-related conditions, including ocular hypertension and glaucoma such as normal tension glaucoma and open angle glaucoma.
    Type: Grant
    Filed: September 21, 2015
    Date of Patent: October 25, 2016
    Assignee: Arrowhead Pharmaceuticals, Inc.
    Inventors: Jon E. Chatterton, Abbot F. Clark, Martin B. Wax
  • RNAi-related inhibition of TNF-alpha signaling pathway for treatment of ocular angiogenesis
    Patent number: 9422556
    Abstract: RNA interference is provided for inhibition of tumor necrosis factor ? (TNF?) by silencing TNF? cell surface receptor TNF receptor-1 (TNFR1) mRNA expression, or by silencing TNF? converting enzyme (TACE/ADAM17) mRNA expression. Silencing such TNF? targets, in particular, is useful for treating patients having a TNF?-related condition or at risk of developing a TNF?-related condition, such as ocular angiogenesis, retinal ischemia, and diabetic retinopathy.
    Type: Grant
    Filed: August 17, 2015
    Date of Patent: August 23, 2016
    Assignee: Arrowhead Pharmaceuticals, Inc.
    Inventors: Jon E. Chatterton, Abbot F. Clark, David P. Bingaman, Martin B. Wax, Adrian M. Timmers
  • RNAi-MEDIATED INHIBITION OF CONNEXIN 43 FOR TREATMENT OF IOP-RELATED CONDITIONS
    Publication number: 20160002638
    Abstract: RNA interference is provided for inhibition of connexin 43 (Cx43) in intraocular pressure-related conditions, including ocular hypertension and glaucoma such as normal tension glaucoma and open angle glaucoma.
    Type: Application
    Filed: September 21, 2015
    Publication date: January 7, 2016
    Inventors: Jon E. Chatterton, Abbot F. Clark, Martin B. Wax
  • RNAi-Related Inhibition of TNF-alpha Signaling Pathway for Treatment of Ocular Angiogenesis
    Publication number: 20150344886
    Abstract: RNA interference is provided for inhibition of tumor necrosis factor ? (TNF?) by silencing TNF? cell surface receptor TNF receptor-1 (TNFR1) mRNA expression, or by silencing TNF? converting enzyme (TACE/ADAM17) mRNA expression. Silencing such TNF? targets, in particular, is useful for treating patients having a TNF?-related condition or at risk of developing a TNF?-related condition, such as ocular angiogenesis, retinal ischemia, and diabetic retinopathy.
    Type: Application
    Filed: August 17, 2015
    Publication date: December 3, 2015
    Inventors: Jon E. Chatterton, Abbot F. Clark, David P. Bingaman, Martin B. Wax, Adrian M. Timmers
  • TRANSFERRIN/TRANSFERRIN RECEPTOR-MEDIATED siRNA DELIVERY
    Publication number: 20150315592
    Abstract: The invention provides interfering RNA molecule-ligand conjugates useful as a delivery system for delivering interfering RNA molecules to a cell in vitro or in vivo. The conjugates comprise a ligand that can bind to a transferrin receptor (TfR). Therapeutic uses for the conjugates are also provided.
    Type: Application
    Filed: July 16, 2015
    Publication date: November 5, 2015
    Inventors: Jon E. Chatterton, Abbot F. Clark
  • RNAi-mediated inhibition of connexin 43 for treatment of IOP-related conditions
    Patent number: 9173896
    Abstract: RNA interference is provided for inhibition of connexin 43 (Cx43) in intraocular pressure-related conditions, including ocular hypertension and glaucoma such as normal tension glaucoma and open angle glaucoma.
    Type: Grant
    Filed: February 13, 2009
    Date of Patent: November 3, 2015
    Assignee: Arrowhead Research Corporation
    Inventors: Jon E. Chatterton, Abbot F. Clark, Martin B. Wax
  • RNAI-MEDIATRED INHIBITION OF FRIZZLED RELATED PROTEIN-1 FOR TREATMENT OF GLAUCOMA
    Publication number: 20150307882
    Abstract: RNA interference is provided for inhibition of Frizzled Related Protein-1 mRNA expression, in particular, for treating patients having glaucoma or at risk of developing glaucoma.
    Type: Application
    Filed: April 21, 2015
    Publication date: October 29, 2015
    Inventors: Abbot F. Clark, Wan-Heng Wang, Loretta Graves McNatt
  • RNAi-related inhibition of TNF alpha signaling pathway for treatment of ocular angiogenesis
    Patent number: 9139834
    Abstract: RNA interference is provided for inhibition of tumor necrosis factor ? (TNF?) by silencing TNF? cell surface receptor TNF receptor-1 (TNFR1) mRNA expression, or by silencing TNF? converting enzyme (TACE/ADAM17) mRNA expression. Silencing such TNF? targets, in particular, is useful for treating patients having a TNF?-related condition or at risk of developing a TNF?-related condition, such as ocular angiogenesis, retinal ischemia, and diabetic retinopathy.
    Type: Grant
    Filed: May 5, 2014
    Date of Patent: September 22, 2015
    Assignee: Arrowhead Research Corporation
    Inventors: Jon E. Chatterton, Abbot F. Clark, David P. Bingaman, Martin B. Wax, Adrian M. Timmers
  • Transferrin/transferrin receptor-mediated siRNA delivery
    Patent number: 9114152
    Abstract: The invention provides interfering RNA molecule-ligand conjugates useful as a delivery system for delivering interfering RNA molecules to a cell in vitro or in vivo. The conjugates comprise a ligand that can bind to a transferrin receptor (TfR). Therapeutic uses for the conjugates are also provided.
    Type: Grant
    Filed: February 12, 2013
    Date of Patent: August 25, 2015
    Assignee: Arrowhead Research Corporation
    Inventors: Jon E. Chatterton, Abbot F. Clark
  • RNAi Inhibition of Serum Amyloid A For Treatment of Glaucoma
    Publication number: 20150225720
    Abstract: RNA interference is provided for inhibition of serum amyloid A mRNA expression in glaucomas involving SAA expression.
    Type: Application
    Filed: February 5, 2015
    Publication date: August 13, 2015
    Inventors: Abbot F. Clark, Wan-Heng Wang, Loretta Graves McNatt
  • RNAi-mediated inhibition of frizzled related protein-1 for treatment of glaucoma
    Patent number: 9040494
    Abstract: RNA interference is provided for inhibition of Frizzled Related Protein-1 mRNA expression, in particular, for treating patients having glaucoma or at risk of developing glaucoma.
    Type: Grant
    Filed: March 26, 2012
    Date of Patent: May 26, 2015
    Assignee: NOVARTIS AG
    Inventors: Abbot F. Clark, Wan-Heng Wang, Loretta Graves McNatt, Jon E. Chatterton
  • RNAi-RELATED INHIBITION OF TNF alpha SIGNALING PATHWAY FOR TREATMENT OF GLAUCOMA
    Publication number: 20150057336
    Abstract: RNA interference is provided for inhibition of tumor necrosis factor ? (TNF?) by silencing TNF? cell surface receptor TNF receptor-1 (TNFR1) mRNA expression, or by silencing TNF? converting enzyme (TACE/ADAM17) mRNA expression. Silencing such TNF? targets, in particular, is useful for treating patients having a TNF?-related condition or at risk of developing a TNF?-related condition such as the ocular conditions associated with elevated intraocular pressure (TOP), including glaucoma and ocular hypertension.
    Type: Application
    Filed: September 12, 2014
    Publication date: February 26, 2015
    Inventors: Jon E. Chatterton, Abbot F. Clark, David P. Bingaman, Martin B. Wax, Adrian M. Timmers